Skip to main content
Signal8
Launch Terminal

MAIA Biotechnology, Inc. (MAIA)

MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

MAIA Biotechnology, Inc. logo

MAIA Biotechnology, Inc.

NYSE:MAIAHealthcare
+1.77%$1.15
AH Close$1.15+0.00%vs close
Mkt Cap$71M
Float52.8M
O/S61.74M
Inst Own21.9%
SI5.1%
Dilution
MAIA Biotechnology, Inc. logoNYSE:MAIA$1.15+1.77%
FormDescription
424B3
Prospectus
4
EFFECT
Notice of Effectiveness
1
8-K
7.01,9.01
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
424B3
Prospectus
4
4
PRIMARY DOCUMENT
S-3
Shelf Registration Statement
3
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
EFFECT
Notice of Effectiveness
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
S-3
Shelf Registration Statement
5
13G/A
Beneficial Ownership Report (Amended)
10-Q
Quarterly Report
6
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT

1-25 of 503

…